Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632.
Noro R, Igawa S, Bessho A, Hirose T, Shimokawa T, Nakashima M, Minato K, Seki N, Tokito T, Harada T, Sasada S, Miyamoto S, Tanaka Y, Furuya N, Kaburagi T, Hayashi H, Iihara H, Okamoto H, Kubota K. Noro R, et al. Lung Cancer. 2021 Nov;161:49-54. doi: 10.1016/j.lungcan.2021.08.007. Epub 2021 Aug 31. Lung Cancer. 2021. PMID: 34536731 Clinical Trial.
The anticancer effect of histone deacetylase inhibitors and combination with the cytotoxic agents in lung cancer cells: biological analyses for future clinical application.
Noro R, Miyanaga A, Shimokawa T, Kuribayashi H, Mizutani H, Minegishi Y, Okano T, Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A, Gemma A. Noro R, et al. J Nippon Med Sch. 2009 Feb;76(1):44-6. doi: 10.1272/jnms.76.44. J Nippon Med Sch. 2009. PMID: 19305113 Free article. No abstract available.
Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R, Miyanaga A, Minegishi Y, Okano T, Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A, Gemma A. Noro R, et al. Cancer Sci. 2010 Jun;101(6):1424-30. doi: 10.1111/j.1349-7006.2010.01559.x. Epub 2010 Mar 10. Cancer Sci. 2010. PMID: 20384633 Free PMC article.
Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.
Kitamura K, Kubota K, Ando M, Takahashi S, Nishijima N, Sugano T, Toyokawa M, Miwa K, Kosaihira S, Noro R, Minegishi Y, Seike M, Yoshimura A, Gemma A. Kitamura K, et al. Among authors: noro r. Cancer Chemother Pharmacol. 2013 Feb;71(2):457-61. doi: 10.1007/s00280-012-2026-4. Epub 2012 Nov 21. Cancer Chemother Pharmacol. 2013. PMID: 23178954
Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer.
Noro R, Yoshimura A, Yamamoto K, Miyanaga A, Mizutani H, Minegishi Y, Seike M, Kubota K, Kosaihira S, Hino M, Ando M, Nomura K, Okano T, Kobayashi K, Uematsu K, Gemma A; East Japan Chesters Group. Noro R, et al. Anticancer Res. 2013 Mar;33(3):1117-23. Anticancer Res. 2013. PMID: 23482789 Clinical Trial.
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.
Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A. Miyanaga A, et al. Among authors: noro r. BMC Cancer. 2013 May 29;13:262. doi: 10.1186/1471-2407-13-262. BMC Cancer. 2013. PMID: 23714228 Free PMC article.
91 results